The feasibility of Goal Attainment Scaling in adults with Down syndrome: early results from the LIFE‐DSR‐GAS sub‐study

Adults with Down syndrome (DS) face a markedly increased risk of Alzheimer’s disease (AD). LIFE‐DSR is a 32‐month longitudinal study of adults with DS aiming to characterize and assess change in cognition, behaviour, function, and health. Goal Attainment Scaling (GAS) is a patient‐centric outcome measure. It evaluates change in goals that are meaningful to participants/caregivers and has proven a valuable and sensitive instrument in dementia clinical trials. To assess the feasibility of using GAS in the DS population and to better understand what is most important to them, the LIFE‐DSR‐GAS sub‐study is enrolling and following participants and their caregivers over 16 months.